Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease

MCA - Middle Cerebral Artery Dissection Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02953405
• Other study ID #: DW_CLO001
• Status: Recruiting
• Phase: N/A
• First received: October 25, 2016
• Last updated: November 1, 2016
• Start date: December 2015
• Est. completion date: November 2018

Study information

• Verified date: October 2016
• Source: Daewoong Pharmaceutical Co. LTD.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• 19 years later, men and women

Exclusion Criteria:

• Subject who is judged to be ineligible by investigator

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Aneurysm, Dissecting
• MCA - Middle Cerebral Artery Dissection

Intervention

Drug:
• Clopidogrel

Locations

Country	Name	City	State
Korea, Republic of	SNUBH	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Daewoong Pharmaceutical Co. LTD.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prescription status of Antithrombotic Agents		at 12 months after baseline(onset)	No